The Top Five Biotech Innovations of the 2000s


Xconomy Seattle — 

[Editor’s Note: As the decade comes to an end, we’ve asked a number of Xconomists around the country to weigh in with the Top 5 innovations they’ve seen in their respective fields the past 10 years, or the Top 5 disruptive technologies that will impact the next decade. Here’s the first installment.]

Here are the 5 biotech innovations from this decade that are currently (or will be shortly) making a big difference for patients with a variety of diseases.

1) Cancer therapies such as Roche/Genentech’s trastuzumab (Herceptin) and Celgene’s lenalidomide (Revlimid).

2) HIV therapies such as Gilead Sciences’ combination of efavirenz, emtricitabine, and tenofovir (Atripla).

3) Improved flu vaccines.

4) Therapies for hepatitis C such as Vertex Pharmaceuticals’ telaprevir.

5) Tumor vaccines such as Dendreon’s sipuleucel-T (Provenge).

Clay Siegall co-founded Seattle Genetics in 1998 and is the company’s President, Chief Executive Officer and a member of the Board of Directors. Follow @

Trending on Xconomy

By posting a comment, you agree to our terms and conditions.

4 responses to “The Top Five Biotech Innovations of the 2000s”

  1. Dave Druker says:

    What about Gleevec?

  2. Dave—I was waiting for someone to chime in with that one. I’m guessing Clay would probably lump that in with his first point about the big cancer drugs of the decade. Other tech leaders that I’m canvassing keep mentioning Gleevec, so that definitely shouldn’t be overlooked.